Clinical characteristics, treatment patterns and relapse in patients with clinical stage IS testicular cancer.
Chemotherapy
Clinical stage IS
Non-seminoma
Seminoma
Tumor markers
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
08
05
2021
accepted:
09
11
2021
pubmed:
3
12
2021
medline:
17
3
2022
entrez:
2
12
2021
Statut:
ppublish
Résumé
Clinical stage I (CSI) testicular germ cell tumors (TGCT) represents disease confined to the testis without metastasis and CSIS is defined as persistently elevated tumor markers (TM) after orchiectomy, indicating subclinical metastatic disease. This study aims at assessing clinical characteristics and oncological outcome in CSIS. Data from five tertiary referring centers in Germany were screened. We defined correct classification of CSIS according to EAU guidelines. TM levels, treatment and relapse-free survival were assessed and differences between predefined groups (chemotherapy, correct/incorrect CSIS) were analyzed with Fisher's exact and Chi-square test. Out of 2616 TGCT patients, 43 (1.6%) were CSIS. Thereof, 27 were correctly classified (cCSIS, 1.03%) and 16 incorrectly classified (iCSIS). TMs that defined cCSIS were in 12 (44.4%), 10 (37%), 3 (11.1%) and 2 (7.4%) patients AFP, ß-HCG, AFP plus ß-HCG and LDH, respectively. In the cCSIS group, six patients were seminoma and 21 non-seminoma. Treatment consisted of active surveillance, carboplatin-mono AUC7 and BEP (bleomycin, etoposide and cisplatin). No difference between cCSIS and iCSIS with respect to applied chemotherapy was found (p = 0.830). 5-year relapse-free survival was 88.9% and three patients (11%) in the cCSIS group relapsed. All underwent salvage treatment (3xBEP) with no documented death. Around 1% of all TGCT were classified as cCSIS patients. Identification of cCSIS is of critical importance to avoid disease progression and relapses by adequate treatment. We report a high heterogeneity of treatment patterns, associated with excellent long-term survival irrespective of the initial treatment approach.
Identifiants
pubmed: 34854948
doi: 10.1007/s00345-021-03889-x
pii: 10.1007/s00345-021-03889-x
pmc: PMC8921055
doi:
Substances chimiques
Etoposide
6PLQ3CP4P3
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
327-334Investigateurs
Maximilian Peter Brandt
(MP)
C Ruf
(C)
I Syring
(I)
T Nestler
(T)
P Albers
(P)
D Nettersheim
(D)
F Zengerling
(F)
P Paffenholz
(P)
Informations de copyright
© 2021. The Author(s).
Références
Albers P et al (2015) Guidelines on testicular cancer: 2015 update. Eur Urol 68(6):1054–1068
doi: 10.1016/j.eururo.2015.07.044
Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, D.K.) (2019) AWMF, S3-Leitlinie Diagnostik, Therapie und Nachsorge der Keimzelltumoren des Hodens. 2019 (Langversion 1.0)
Kamran SC et al (2018) Contemporary treatment patterns and outcomes for clinical stage IS testicular cancer. Eur Urol 73(2):262–270
doi: 10.1016/j.eururo.2017.06.013
Faber KD et al (2014) Validation of surveillance, epidemiology, and end results TNM staging for testicular germ cell tumor. Urol Oncol 32(h8):1341–1346
doi: 10.1016/j.urolonc.2014.04.004
Wymer KM et al (2017) Mildly elevated serum alpha-fetoprotein (AFP) among patients with testicular cancer may not be associated with residual cancer or need for treatment. Ann Oncol 28(4):899–902
doi: 10.1093/annonc/mdx012
Dash A et al (2008) The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor. Cancer 112(4):800–805
doi: 10.1002/cncr.23233
Culine S et al (1996) Primary chemotherapy in patients with nonseminomatous germ cell tumors of the testis and biological disease only after orchiectomy. J Urol 155(4):1296–1298
doi: 10.1016/S0022-5347(01)66248-7
Ahmed KA, Wilder RB (2014) Outcomes and treatment patterns as a function of time in stage IS testicular seminoma: a population-based analysis. Cancer Epidemiol 38(2):124–128
doi: 10.1016/j.canep.2014.02.003
Ackers C, Rustin GJ (2006) Lactate dehydrogenase is not a useful marker for relapse in patients on surveillance for stage I germ cell tumours. Br J Cancer 94(9):1231–1232
doi: 10.1038/sj.bjc.6603087
Kotoh K et al (2011) Lactate dehydrogenase production in hepatocytes is increased at an early stage of acute liver failure. Exp Ther Med 2(2):195–199
doi: 10.3892/etm.2011.197
Augoff K, Hryniewicz-Jankowska A, Tabola R (2015) Lactate dehydrogenase 5: an old friend and a new hope in the war on cancer. Cancer Lett 358(1):1–7
doi: 10.1016/j.canlet.2014.12.035
Mythili S, Malathi N (2015) Diagnostic markers of acute myocardial infarction. Biomed Rep 3(6):743–748
doi: 10.3892/br.2015.500
Dieckmann KP et al (2019) Serum tumour markers in testicular germ cell tumours: frequencies of elevated levels and extents of marker elevation are significantly associated with clinical parameters and with response to treatment. Biomed Res Int 2019:5030349
doi: 10.1155/2019/5030349
Dieckmann KP et al (2017) Pure testicular seminoma with non-pathologic elevation of alpha fetoprotein: a case series. Urol Int 99(3):353–357
doi: 10.1159/000478706
Patel P, Balise R, Srinivas S (2012) Variations in normal serum alpha-fetoprotein (AFP) levels in patients with testicular cancer on surveillance. Onkologie 35(10):588–591
doi: 10.1159/000342695
Dieckmann KP et al (2019) Serum levels of microRNA-371a-3p (M371 test) as a new biomarker of testicular germ cell tumors: results of a prospective multicentric study. J Clin Oncol 37(16):1412–1423
doi: 10.1200/JCO.18.01480
Kollmannsberger C et al (2015) Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance. J Clin Oncol 33(1):51–57
doi: 10.1200/JCO.2014.56.2116
Tandstad T et al (2010) Long-term follow-up after risk-adapted treatment in clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT) implementing adjuvant CVB chemotherapy. A SWENOTECA study. Ann Oncol 21(9):1858–1863
doi: 10.1093/annonc/mdq026
Gilligan T et al (2019) Testicular cancer, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 17(12):1529–1554
doi: 10.6004/jnccn.2019.0058
Davis BE et al (1994) The management of patients with nonseminomatous germ cell tumors of the testis with serologic disease only after orchiectomy. J Urol 152(1):111–113 (discussion 114)
doi: 10.1016/S0022-5347(17)32830-6
Saxman SB, Nichols CR, Einhorn LH (1994) Salvage chemotherapy in patients with extragonadal nonseminomatous germ cell tumors: the Indiana University experience. J Clin Oncol 12(7):1390–1393
doi: 10.1200/JCO.1994.12.7.1390
Aparicio J et al (2019) Treatment and outcome of patients with stage IS testicular cancer: a retrospective study from the Spanish germ cell cancer group. J Urol 202(4):742–747
doi: 10.1097/JU.0000000000000366
Tandstad T et al (2009) Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J Clin Oncol 27(13):2122–2128
doi: 10.1200/JCO.2008.18.8953
Tandstad T et al (2016) Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA). Ann Oncol 27(7):1299–1304
doi: 10.1093/annonc/mdw164